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Abstract
Objectives—To utilize a non-biased assay of circulating tumour cells (CTCs) in prostate cancer 
(PCa) patients in order to identify non-traditional CTC phenotypes potentially excluded by 
conventional detection methods reliant upon antigen and/or sized based enrichment.
Patients and Methods—41 metastatic castration resistant prostate cancer (mCRPC) patients 
and 20 healthy volunteers were analysed on the Epic CTC Platform, via high throughput imaging 
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of DAPI expression and CD45/cytokeratin (CK) immunofluorescence (IF) in all circulating 
nucleated cells plated on glass slides. IF for androgen receptor [AR] expression, and FISH for 
PTEN and ERG confirmed PCa origin of CTCs.
Results—Traditional (t) CTCs (CD45−/CK+/morphologically distinct) were identified in 100% 
mCRPC patients. Using the above markers, we identified non-traditional CTCs in mCRPC 
patients, including CK− and apoptotic CTCs. Small CTCs (≤WBC size) were identified in 98% of 
mCRPC patients. Total, traditional and non-traditional CTCs were significantly increased in 
deceased vs. living patients at 18 months; however only non-traditional CTCs associated with 
overall survival. Traditional and total CTC counts by the Epic platform in the mCRPC cohort were 
also significantly correlated with CTC counts by the CellSearch system.
Conclusions—Heterogeneous non-traditional CTC populations that may be missed by other 
approaches are frequent in mCRPC; characterization of non-traditional CTCs may provide 
additional prognostic or predictive information.
Keywords
Circulating tumour cells; liquid biopsy; metastatic castration resistant prostate cancer; ERG; 
PTEN
INTRODUCTION
Dissemination of cancer cells from primary sites into circulation and seeding of metastases 
is the underlying cause of mortality for most non-hematopoietic malignancies. Detection and 
enumeration of circulating tumour cells (CTCs) is associated with decreased progression-
free survival and overall survival for a variety of tumours, including prostate cancer (PCa) 
[1–3]. Based on these findings, CTC enumeration could be a valuable tool for disease 
response and progression monitoring. Additionally, CTCs can also be characterized for 
predictive biomarkers. Given that CTCs circulate at very low concentrations (10−6–10−7) 
[4], detection in millilitres of blood requires extremely sensitive and specific methods. 
Numerous technologies have been developed to this end [5, 6], with the majority requiring 
an enrichment step based on differences in various physical (size and/or density) or 
biological parameters (surface marker expression) to distinguish CTCs from surrounding 
hematopoietic cells. For example, the CellSearch® Circulating Tumor Cell System, the only 
FDA cleared method for CTC detection [7], requires cells to contain a DAPI-intact nucleus, 
lack expression of the hematopoietic marker CD45, express epithelial cell adhesion 
molecule (EpCAM) and cytokeratin (CK), and have a diameter larger than 4 μm [7]. 
Enrichment technologies however will potentially fail to capture non-traditional tumour cells 
lacking the selected characteristic.
Indeed, recent reports utilizing non-EpCAM or size based selection techniques have 
underscored this point, revealing PCa CTCs with non-traditional phenotypes, describing 
heterogeneity in size [8], epithelial marker expression [9], cell integrity [10], and 
proliferation rate [11]; both between and within individual patients. CTCs isolated from men 
with metastatic PCa have also shown evidence of epithelial-mesenchymal transition (EMT), 
via detection of EMT related transcription factors, expression of N-cadherin and vimentin, 
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and loss of CK and E-cadherin expression [9]. However, the degree and scope of this 
heterogeneity within PCa CTC populations is incompletely described, as most approaches 
are only able to assess heterogeneity in a single parameter.
Numerous studies have identified a relationship between CTC counts and disease 
progression or overall survival in metastatic castrate-resistant prostate cancer (mCRPC) [2, 
3]. These studies have been based on single-parametric enrichment technologies which 
likely miss non-traditional CTC phenotypes that may have prognostic or therapeutic 
significance. Here, we utilize a non-biased assay technique (the Epic CTC platform) that 
retains all nucleated cells and interrogates them in a multi-parametric fashion, analysing 
size, shape, DAPI staining and immunofluorescence (IF) antigen characterization (typically 
CD45 and CK expression). Concurrently, we evaluated both traditional (CD45−, CK+, 
morphologically distinct) and candidate non-traditional CTCs for PCa-specific molecular 
aberrations, including androgen receptor (AR) expression by IF, and PTEN deletion and 
ERG rearrangement by fluorescence in situ hybridization (FISH) [12–15]. Through this 
approach, we demonstrate that patients with mCRPC harbour a variety of non-traditional 
CTC phenotypes.
PATIENTS AND METHODS
Sample Collection and Handling
Whole blood samples were obtained from 41 unique patients, required to have histologically 
or biochemically confirmed prostate adenocarcinoma and planned for initiation of a new 
treatment for progressive mCRPC in the presence of castrate levels of serum testosterone 
(<50 ng per decilitre [1.73 nmol per litre]), consistent with Prostate Cancer Clinical Trials 
Working Group 2 (PCWG2) guidelines. After collection at the Royal Marsden, Sutton, UK, 
samples were shipped to Epic Sciences (San Diego, CA, USA) at ambient temperature. 
Sample collection for this study was approved by The Royal Marsden (London, UK) 
Research Ethics Committee (REC 04/Q0801/6) and by The Royal Marsden Committee for 
Clinical Research. Additionally, 21 samples were obtained from 20 consenting healthy 
adults by The Institute of Cancer Research (London, U.K.) or Epic Sciences (San Diego, 
CA, USA) and processed in the same manner as patient samples. All samples were collected 
with informed consent. Patient and healthy volunteer demographics are summarized in Table 
1. The median blood sample transit time for patient samples was 32 hours with a range of 
28–78 hours. Additional draws from select patients were evaluated as needed for FISH.
Blood sample preparation and storage
Upon sample receipt, red blood cells were lysed and nucleated cells dispensed onto glass 
microscope slides according to methods previously described [16–18]. Up to 12 slides were 
prepared from each blood sample at 3×106 cells/slide. Slides were then stored at −80°C 
(stable for longer than one year, unpublished data). The number of slides created from each 
individual sample was determined by the volume of blood received and the white blood cell 
(WBC) count.
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CTC identification and protein characterization on the Epic platform
For CTC analysis, two slides from each patient sample were thawed, then stained by IF to 
distinguish CTCs from WBCs as described previously [16–18]. In addition to DAPI, CD45, 
and CK, an additional antibody targeting the N-terminal region of AR (clone D6F11, Cell 
Signalling Technology, Danvers, MA, USA) was utilized, capable of detecting full length 
and LBD-truncated variants of the protein. Stained slides were imaged on a high-speed 
fluorescent imaging system. Captured images were analysed by an automated algorithm that 
characterizes each cell by more than 90 parameters, including protein expression and 
morphology to distinguish CTCs from normal nucleated cells. All CTC candidates were then 
reviewed by trained technicians, and CK+/CD45− cells with intact, DAPI+ nuclei exhibiting 
tumour-associated morphologies were classified as traditional CTCs. The trained technicians 
were blinded as to whether the sample was from a cancer patient or healthy donor. Candidate 
CTCs that did not meet the criteria for traditional CTC, as described in the Results, were 
identified as CD45−/CK− cells with abnormal morphology or apoptotic CTCs (CD45− with 
characteristic nuclear fragmentation or condensation). In a separate subsequent analysis, cell 
morphological characteristics, including cell area, were determined for each CTC by Epic 
proprietary software. Analysis was reviewed by a Board certified Anatomic Pathologist with 
experience in genitourinary pathology and molecular characterization of mCRPC (S.A.T.) to 
confirm cancer origin.
CTC analysis via CellSearch Assay
CTC isolation and enumeration were carried out using the CellSearch™ system (Janssen 
Diagnostics, Raritan, NJ, USA) according to the manufacturer’s instructions. Blood samples 
were drawn into CellSave™ tubes (Janssen Diagnostics) and samples were kept at room 
temperature and processed within 72 h of collection. To calculate the CTC count, 7.5 ml of 
blood was enriched immunomagnetically using anti-EpCAM antibodies, followed by 
fluorescent labelling and individual capture using a four-colour semiautomated fluorescent 
microscope. The images were then presented to trained operators, who selected cells that 
met the definition of CTC. Criteria used to define a CTC include round to oval morphology, 
size >5 μm, a visible nucleus (4′,6-diamidino-2-phenylindole positive), positive staining for 
cytokeratins 8,18 and/or 19 (phycoerythrin) and negative staining for CD45 
(allophycocyanin). Results were expressed as the number of cells per 7.5 ml of blood.
CTC FISH analysis
Following CTC IF analysis, a subset of slides with a sufficient number of CTCs was tested 
for PTEN loss or ERG rearrangements by fluorescence in situ hybridization (FISH). 
Coverslips were removed and slides were hybridized using a two-color probe solution 
targeting either PTEN and chromosome 10 centromere (CC10) DNA sequences or regions 
flanking 5′ and 3′ ERG (Cymogen Dx, New Windsor, NY, USA). After processing, slides 
were counterstained with DAPI and mounted with an anti-fade mounting medium. Epic 
software was used to relocate CTCs for scoring. A minimum of 20 WBCs on each slide 
were also scored as internal controls.
PTEN loss was defined by a cell containing fewer PTEN signals than CC10 signals or only 
one of each signal (loss of chromosome 10). Cells with no PTEN signals and at least one 
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CC10 signal were classified as homozygous PTEN loss (HO). Heterozygous PTEN loss 
(HE) cells contained at least one PTEN signal and either more CC10 signals than PTEN or 
one PTEN signal and one CC10 signal. Cells with a 1:1 ratio of PTEN:CC10 and at least 
two of each signal were considered PTEN non-deleted. ERG rearrangements can present as 
a split of the 5′ and 3′ FISH signals (representing ERG fusions though insertion, inversion 
or translocation) or as a deletion of the 5′ FISH signal (representing TMPRSS2:ERG 
fusions through deletion of the intervening region on chromosome 21). Hence, cells were 
considered ERG-rearranged if a separation of at least one pair of 5′ and 3′ ERG signals (by 
a distance of at least 2 signal diameters) or a deletion of at least one 5′ ERG signal was 
observed. Cells in which all 3′ ERG signals had a corresponding 5′ ERG signal within two 
signal diameters were considered ERG non-rearranged.
Statistical Analysis
Correlations/associations of traditional and non-traditional CTC counts and 
clinicopathological parameters were assessed by Spearman rank correlation, two-sided 
Mann-Whitney tests, Kruskal-Wallis tests or Kaplan-Meier analysis using MedCalc v 15.6 
(MedCalc Software bvba, Belgium). Area under the curve (AUC) from receiver operator 
characteristic (ROC) curves was determined using MedCalc v 15.6 for traditional and non-
traditional CTC counts for predicting mCRPC vs. healthy volunteer status. Youden index 
CTC/mL cutoff, value, and CTC cutoffs with sensitivity and specificity at 100% specificity 
and sensitivity, respectively, were determined as part of the ROC analysis. Kaplan-Meier 
analysis was performed by stratifying patients per CTC type into those with ≤ vs. > median 
CTC count. For all tests, p values < 0.05 were considered significant.
RESULTS
Detection of Traditional CTCs in mCRPC patients
A total of 41 blood samples from 41 mCRPC patients and 21 blood samples from 20 healthy 
volunteers were analysed. Patient and healthy volunteer demographics are shown in Table 1. 
An average of 11 slides per patient was plated (range 4 to 16) from an average blood volume 
of 7.0 mL per patient (range 3.68–7.83 mL). Traditional CTCs were defined (described 
previously [16–18]) as cells with an intact, DAPI-positive nucleus lacking features of 
apoptosis, absence of CD45 staining (CD45−) and positive CK staining (CK+) (Figure 1). 
Additionally, traditional CTCs were required to have characteristic cytomorphologic features 
consistent with malignancy (including nucleomegaly, nuclear membrane irregularity, 
eccentric cytoplasmic distribution, and polygonal/elongated cell shapes) [16–19]. Using this 
traditional CTC definition, 41/41 (100%) mCRPC patients had detectable traditional CTCs 
(median 5/mL, range 1–121) and 22/41 (54%) had >4/mL.
When two or more adjacent traditional CTCs were identified, they were classified as CTC 
clusters. CTC clusters were detected in 7/41 (17%) patients (median 0/mL, range 0–6) 
(Figure 1). Of 20 healthy volunteers tested, none had >4 events in 1mL meeting the 
definition for a traditional CTC and five (25%) had 1–4/mL (median 0/mL, range 0–4/mL, 
see Figure 2 for representative events in healthy volunteers). CTC clusters were not detected 
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in healthy volunteer samples. Figure 3 shows the frequency of traditional CTCs and CTC 
clusters in patient samples compared to healthy volunteer samples.
ROC curve analysis of traditional CTC counts, CTC clusters (as well as other non-traditional 
CTCs as described below) to discriminate healthy volunteers from mCRPC patients—
although not the intended use of the assay— was performed for each traditional and non-
traditional CTC type. The area under the curve (AUC) for prediction of CRPC status for 
traditional CTCs (CTCs/mL), CTC clusters, CK− CTCs, apoptotic CTCs and all CTCs was 
0.93 (Youden index 0.71 at >0 CTCs/mL), 0.59 (Youden index 0.17 at >0 CTCs/mL), 0.91 
(Youden index 0.78 at >0 CTCs/mL), 0.91 (Youden index 0.74 at >4 CTCs/mL) and 0.96 
(Youden index 0.76 at >4 CTCs/mL), as shown in Table 2..
Phenotypic and Molecular Characterization of Traditional CTCs
AR over-expression, loss of PTEN, and ERG rearrangements (most commonly resulting in 
TMPRSS2:ERG gene fusions) are common molecular events in mCRPC and can be used to 
confirm captured cells are CTCs, especially ERG rearrangements that are PCa specific [12–
15]. AR expression was evaluated in all mCRPC patients and select healthy volunteers. To 
generate a relative AR expression value for each CTC, Epic’s software normalized AR 
expression in CTCs to approximately 1 million surrounding CD45+ WBCs present on the 
same slide, resulting in CTCs with AR expression values ≥3.0 being considered positive. 
Across the 41 mCRPC patients, 28 (68%) had at least one AR-positive traditional CTC/mL 
(range 0–96) (Figure 4A). The proportion of AR+ to AR− traditional CTCs was variable 
(Figure 4B). Of six healthy volunteer samples tested, none had >1 AR+ CTC/mL.
To further establish the prostatic origin of CTCs in our cohort, we also assessed PTEN and 
ERG status by FISH, using surrounding WBCs as internal controls. To determine assay 
specificity, we assessed PTEN and ERG status of WBCs from patient slides tested by FISH. 
Of 120 patient WBCs evaluated for PTEN FISH, 3 (2.5%) and 0 (0.0%) cells were detected 
with PTEN heterozygous (HE) and homozygous (HO) loss, respectively, resulting in 97.5–
100% specificity of PTEN FISH on the Epic platform. Of 220 patient WBCs evaluated with 
ERG FISH, 10 (4.5%) and 0 (0.0%) cells had a split signal or loss of the 5′ probe 
confirming 95.5–100% specificity.
After IF staining for CTC and AR detection on the Epic platform, CTCs from select mCRPC 
patients were then re-located and evaluated for PTEN and/or ERG FISH status. PTEN 
deletions (HE and/or HO) were detected in traditional CTCs from 4 of 5 patients evaluated 
(Table 3). Likewise, ERG rearrangements (translocation and/or deletion) were identified in 
traditional CTCs from 5 of 6 patients evaluated (Table 3). Representative images of 
traditional CTCs with AR expression and/or PTEN deletion or ERG rearrangement are 
shown in Figure 1. Among slides from healthy volunteers, none had sufficient detectable 
CTCs to perform PTEN or ERG assessment.
PTEN FISH was performed on 5 representative patients with CK− CTCs and we were able 
to evaluate 18 CK− CTCs from 3 patients. Of 3 patients with evaluable CK− CTCs, PTEN 
deletions were identified in 1 patient, with 5/9 (56%) CK− CTCs showing PTEN deletion. 
PTEN deletions were also detected in 4/11 (36%) traditional CTCs from this patient. ERG 
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FISH was performed on 6 representative patients with CK− CTCs and we were able to 
evaluate 26 CK− CTCs from 5 patients. Of 5 patients with evaluable CK− CTCs, ERG 
rearrangements were identified in 3 patients, with 3/26 (12%) CK− CTCs showing ERG 
rearrangement. ERG rearrangements were also detected in 18/108 (17%) traditional CTCs 
from these 3 patients.
Small CTCs were evaluated in select patient samples by FISH for ERG and PTEN 
aberrations. ERG FISH was performed on 6 patients with small CTCs and we were able to 
evaluate 27 small CTCs from 3 patients. Of these, ERG rearrangements were detected in 1 
patient in 6/23 (26%) small CTCs. ERG rearrangements were also detected in 18/73 (25%) 
traditional CTCs (non-small) from this patient. The size of small CTCs precluded 
interpretation of PTEN deletions in all but 3 small CTCs in 2 patients, which were wild type. 
Examples of small CTCs harbouring AR positivity by IF or ERG alterations by FISH are 
shown in Figure 1. Importantly, these results demonstrate the utility of this assay to 
characterize CTC populations with cancer-specific markers, verifying the prostatic origin of 
traditional CTCs in this cohort.
Detection of Non-traditional CTCs in mCRPC patients
As described in detail below, we identified two categories of cells with non-traditional 
phenotypes (in addition to CTC clusters) that were potential CTCs: cells with weak or no 
CK expression (CK− CTCs), and cells with degenerative changes and nuclear disintegration 
consistent with apoptosis (apoptotic CTCs). All patients harboured circulating cells with 
these non-traditional phenotypes (median 6/mL, range 1–101). Four of 20 (20%) healthy 
volunteers had circulating cells that met these expanded CTC criteria (median 0/mL, range 
0–5) and 3/20 (15%) had cells with AR positivity (median 0/mL per patient, range 0–4). 
Figure 3 shows the frequency of non-traditional CTCs in patient samples compared to 
healthy volunteer samples. For all non-traditional CTCs, AR expression was evaluated by IF 
and showed a wide variability similar to traditional CTCs (Figure 4A). Representative 
images of non-traditional CTCs, including those with PCa specific molecular alterations, are 
shown in Figure 1.
Cytokeratin-negative CTCs
CK intensity in CD45− circulating cells with abnormal morphology varied widely across 
patients with mCRPC (Figure 4C). As with AR expression measurements, relative CK 
expression values for every CTC were generated by Epic’s software, normalizing CK 
expression in CTCs to approximately 1 million surrounding CD45+ WBCs present on the 
same slide. CTCs with CK expression values ≥2.8 were considered positive (signal ≥ 2.8 
fold higher than background WBCs). Hence, we defined non-traditional CK− CTCs as 
CD45− circulating cells with morphological distinction and/or AR positivity, but CK 
intensity less than 2.8. Such CK− CTCs were identified in 34/41 (83%) mCRPC patients 
(median 2 CK− CTC/mL, range 0–20). Amongst patients with CK− CTCs, 26 (76%) had at 
least 1 AR+ CK− CTC/mL (range 0–20). The proportion of CK+/CK− CTCs varied across 
the cohort, with two patients demonstrating a CTC population that was predominantly CK− 
(Figure 4D). Of healthy volunteers evaluated, none had >1 CD45−/CK− cell/mL. Both ERG 
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rearrangements and PTEN deletions were detected in CK− CTCs from mCRPC patients who 
harboured these same alterations in traditional CTCs (Table 3).
Apoptotic and Small CTCs
CD45−/CK+ cells with nuclear fragmentation or condensation characteristic of apoptosis 
were also observed across the mCRPC cohort. These cells, which we classified as non-
traditional apoptotic CTCs, were detected in 40/41 (98%) of mCRPC patients (median 
4/mL, range 0–92) as shown in Figure 3. Of the 40 patients with apoptotic CTCs, 31 (78%) 
had at least 1 AR+ apoptotic CTC/mL (range 0–60). Similar to the other categories of non-
traditional CTCs, the frequency of apoptotic CTCs varied among mCRPC patients, with 
11/41 (27%) patients exhibiting CTC populations composed primarily of apoptotic CTCs 
(Figure 4E). Due to nuclear fragmentation or disintegration, apoptotic CTCs were not 
amenable to FISH analysis.
We then utilized Epic software to objectively measure the total cell area of each CTC to 
elucidate the subpopulations of CTCs in patient samples that were similar in size to (or 
smaller than) WBCs, that could potentially be missed by size or density enrichment 
strategies for CTC isolation. Approximately 300 patient WBCs were used to generate the 
median and interquartile ranges for WBC area (75 μm2 and 64–90 μm2, respectively). We 
therefore used a cell area ≤ 90 μm2 to define a small CTC (Figure 5A). By this approach, 
cell area of traditional and non-traditional CTC subtypes was evaluated for 40/41 patient 
samples (1 sample was not evaluable by this method and omitted from analysis). Apoptotic 
CTCs were omitted from analysis because of poor segmentation due to fragmented cell 
morphology. We observed a wide range of CTC sizes within individual patients and across 
the mCRPC patient cohort using this objective assessment, with small CTCs detectable in 
39/40 (97.5%) mCRPC patients. CTCs detected in mCRPC patients had a median cell area 
of 99.0 μm2 (range 28.9–1631.0). The proportion of small CTCs (CTCs with cell area ≤ 90 
μm2) is shown for each patient in Figure 5B, with 17/40 (42.5%) patients exhibiting CTC 
populations composed predominantly of small CTCs. Small CTCs were evaluated in select 
patient samples by FISH for ERG and PTEN aberrations (Table 3). Examples of small CTCs 
harbouring AR positivity by IF or ERG alterations by FISH are shown in Figure 1.
Clinical significance of CTC types
Although the main focus of our work was to define the morphologic and phenotypic range 
of CTCs in patients with mCRPC using an unbiased approach complemented by molecular 
characterization, we also assessed associations between traditional and non-traditional CTC 
types and clinicopathological parameters (serum prostate-specific antigen (PSA), lactate 
dehydrogenase (LDH), albumin and hemoglobin levels, as well as prior treatment regimens 
and presence of visceral metastasis). Importantly, as shown in Figure 6A, this analysis 
demonstrated that counts of all CTC types detected by the Epic platform (traditional, CTC 
clusters, and each non-traditional CTC type, as well as the sum of all CTCs) are significantly 
correlated with each other, ranging from Spearman rank correlation (rs) = 0.35 for apoptotic 
CTC and CTC cluster counts (p=0.03), to rs=0.72 for traditional CTC and apoptotic CTC 
counts (p<0.0001). Of interest, there was no significant correlation between any CTC type 
count and serum PSA levels. However, counts of CTC types other than CTC clusters were 
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significantly associated with high LDH and low albumin, two important prognostic 
parameters. Likewise, both all CTC (sum of traditional CTCs, CTC clusters, apoptotic CTCs 
and CK− CTCs) and apoptotic CTC counts were significantly associated with the presence 
of visceral metastasis Figure 6B. We did not identify a statistically significant difference 
between any CTC type count and prior treatment regimen.
Next, we assessed correlations between CTC counts by the CellSearch Circulating Tumor 
Cell System and the Epic platform in the mCRPC cohort. Importantly, as shown in Table 4, 
we observed strong correlation between traditional CTC counts by CellSearch and 
traditional CTCs by the Epic platform in the mCRPC patients (Pearson’s correlation r = 
0.78, p<0.0001). Likewise, we also observed significant correlations between CellSearch 
CTC counts and apoptotic (Pearson’s correlation r = 0.91, p<0.0001) or CK− CTC counts (r 
= 0.39, p=0.02) by the Epic platform (Table 4). No significant correlation was observed 
between CellSearch CTC counts and CTC cluster counts (r = −0.07, p=0.68) by the Epic 
platform, although CTC clusters were infrequently observed in our cohort. Importantly, we 
identified a strong, significant correlation between CellSearch CTC counts and total CTC 
counts by the Epic Platform (r = 0.89, p<0.0001, Table 4).
Lastly, to provide preliminary insight into associations with clinical outcome, we determined 
CTC counts by the Epic Platform in mCRPC patients who were alive or dead after 18 
months (40 of 41 patients with sufficient follow-up). As shown in Figure 6C, total, 
traditional and non-traditional (clusters, apoptotic and CK−) CTC counts were significantly 
higher in patients dead versus alive at 18 months (Mann-Whitney test, p=0.02, p=0.03 and 
p=0.04, respectively). By Kaplan-Meier analysis on all 41 patients, the number of non-
traditional CTCs was significantly associated with overall survival (, > vs. ≤ median CTC 
count, p=0.03, Fig 4D). Results for individual non-traditional CTC types are shown in 
Figure 7. Of interest, there were 14 patients with <5 CTCs detected by the CellSearch assay, 
of which 4 were deceased at 18 months; each of these deceased patients demonstrated non-
traditional CTC cells as detected by the Epic platform.
DISCUSSION
To characterize the phenotypic diversity of CTCs in mCRPC, we used the Epic platform to 
characterize all nucleated cells from whole blood samples [20]. Using DAPI, CD45, CK and 
AR IF, we identified and morphologically characterized cells with cancer-associated 
features, irrespective of whether they met the traditional CTC definition. We then used FISH 
and slide scanning with single-cell resolution to confirm that sub-populations of non-
traditional CTCs were PCa in origin. We detected non-traditional CTC in all patients, 
including CTC clusters, small, apoptotic and/or CK− CTCs. We also observed intra-patient 
heterogeneity of AR and CK expression and PTEN and ERG status consistent with a 
heterogeneous model of advanced disease, as has been observed in recent studies of CRPC 
assessing AR expression in CellSearch-isolated CTCs, metastatic tissues assessed by whole 
genome sequencing, and circulating cell free DNA assessed using targeted next generation 
sequencing [21–23].
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Although non-traditional CTC counts correlated with traditional CTC counts, substantial 
variation in the proportions of traditional to non-traditional CTCs were observed. 
Importantly, some CTCs we identified could be missed by CTC detection platforms using 
antigen capture (i.e. EpCAM or CK) or size selection (such as filtration). In keeping with 
this idea, Chen et al., recently reported that EpCAM captured CTCs (enriched using 
NanoVelcro Chips) in patients with mCRPC showed variable nuclear size, and patients with 
visceral metastases specifically showed elevated very small nuclear sized CTCs [8]. Our 
results suggest that in addition to nuclear size variability, CTCs in mCRPC patients show 
considerable heterogeneity in nuclear organization, and CK and AR expression.
CK+/CD45− cells were identified in a small minority of healthy volunteer samples at low 
frequencies, with the majority demonstrating low CK and AR expression. Given no 
universally established reference range for the definition of CTC, nor a recognized pan-CTC 
marker, it is difficult to discern the relevance of these cells in healthy volunteers. CTC-like 
cells can be detected in the blood of patients with benign conditions as well as in those with 
early stage disease [24–26], and have been reported in labelled healthy volunteers [27]. The 
ideal healthy volunteer or non-cancer control population would be matched in age and 
demographics, with confirmed absence of malignancy. While these caveats are impediments 
for utilizing any CTC platform for the primary diagnosis of prostate cancer, the increased 
sensitivity and specificity of the Epic platform for CTC detection could be suited for 
acquiring prognostic and predictive information in mCRPC patients.
Detection of significant non-traditional CTC populations in mCRPC patients is consistent 
with substantial evidence supporting their existence and clinical relevance. For example, 
CTCs postulated to have undergone epithelial to mesenchymal transition (EMT), and 
displaying reduced/no EpCAM or CK expression, have been identified by multiple 
platforms using both cell lines and patient samples [27–33]. These cells may be enriched for 
multipotent cancer stem cells, with increased self-renewal and metastasis forming capacity 
[34, 35]. Although prior studies demonstrate substantial heterogeneity of PTEN deletion 
status in CTCs and CRPC tissue foci in a given patient [12, 36], ERG rearrangements have 
generally been identified as a clonal alteration (when present) in both CTCs and mCRPC 
tissues [12, 21, 37–39]. Possible explanations for these apparently discrepant results include 
increased sensitivity for traditional and non-traditional CTCs (identified here) that may 
represent multiple clonal populations when compared to our previous CellSearch based 
study showing homogeneous ERG status in traditional CTCs [12]. Also, our recent study on 
circulating cell-free DNA in patients with mCRPC supported the existence of both ERG 
rearranged and wildtype clones in the same patient during disease progression [23]. This 
contrasts with the observation that multiple CRPC foci at autopsy in an individual patient 
nearly always show homogeneous ERG status. Further studies are required to interrogate 
this difference, which we hypothesize could be informed by more comprehensive genetic 
analysis of individual traditional and non-traditional CTC populations.
Our cohort represents a single institution mCRPC cohort and the relatively small size in this 
non-uniformly treated initial study limits the ability to draw robust conclusions on 
associations between non-traditional CTCs and clinical outcome. Likewise, additional 
studies are needed to characterize the metastatic potential of distinct CTC classes. 
McDaniel et al. Page 10
BJU Int. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Importantly, evaluation of these distinct CTC populations described here in larger, well-
defined cohorts to inform on their prognostic and predictive utility in mCRPC is now 
warranted. Here, using pathologic and molecular biological approaches, we have described 
expanded categories of CTC phenotypes in patients with mCRPC and demonstrate that 
considerable heterogeneity exists within these categories. These expanded CTC subtypes 
may provide novel prognostic and predictive information for patients with mCRPC, as well 
as other advanced cancers. Intriguing preliminary clinical associations between mCRPC 
outcomes and various CTC subpopulations will need to be assessed in additional ongoing 
and planned studies to expand on our study.
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Figure 1. Patients with metastatic castration resistant prostate cancer (mCRPC) harbour 
traditional and non-traditional CTCs with prostate cancer specific molecular alterations
A. Representative immunofluorescence (IF) image (100× magnification) examples of 
traditional and non-traditional CTCs in mCRPC patient samples (positive androgen receptor 
(AR) staining by IF is shown for each CTC). Traditional (DAPI+/CD45−/cytokeratin [CK]+/
abnormal morphology), cluster (two or more adjacent traditional CTCs), small (DAPI+/
CD45−/CK+/small cellular area), CK− (DAPI+/CD45−/CK−/AR+/abnormal morphology), 
and apoptotic (DAPI+/CD45−/CK+/nuclear disintegration/abnormal morphology) CTCs 
from mCRPC patient samples are shown. B. Example photomicrographs (400× 
magnification) of ERG and PTEN molecular alterations detected by fluorescence in situ 
hybridization (FISH) in traditional and non-traditional CTCs from mCRPC patient samples 
are shown (inset images (100× magnification) show CTC prior to FISH). PTEN deletions 
are indicated by loss of the PTEN locus green signal) in the presence of chromosome 10 
centromeric signal (CEP 10, red). ERG rearrangements can be identified by 5′ deletion 
(resulting in loss of 5′ green signal; far left panel) or by split 5′/3′ signals (centre and 
second from right panel).
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Figure 2. CTC-like cells detected in healthy volunteers
Representative immunofluorescence (IF) examples (100× magnification) of traditional and 
non-traditional CTC-like cells in healthy volunteer samples. Traditional (DAPI+/CD45−/
cytokeratin [CK]+/abnormal morphology), CK− (DAPI+/CD45−/CK−/AR+/abnormal 
morphology), and apoptotic (DAPI+/CD45−/CK+/nuclear disintegration/abnormal 
morphology) CTC-like cells from healthy volunteers are shown. Blue = DAPI, green = 
CD45, Red = CK, White = AR.
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Figure 3. CTC incidence in mCRPC patient samples compared to healthy volunteers (HV)
A. The number of traditional CTCs, CTC clusters, CK− CTCs, apoptotic CTCs and all CTC 
candidates (traditional, clusters, CK−, and apoptotic CTCs)/mL identified in HV and 
mCRPC patient samples are plotted. Black lines indicate the median CTCs/mL. B. Range, 
median, and mean CTCs/mL in mCRPC patient samples for all categories are given.
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Figure 4. AR and CK expression by immunofluorescence varies across traditional and non-
traditional CTCs in mCRPC patient samples
AR (A&B) and CK (C&D) intensity distribution across traditional and non-traditional CTCs 
per patient. The dashed lines at 3 (A) and 2.8 units (C) indicate the cut-off for AR and CK 
positivity, respectively. Charts B and D show the percentage of all CTCs/mL (traditional and 
non-traditional) with or without B) AR or D) CK expression per patient. E. The percentage 
of apoptotic and non-apoptotic CTCs/mL per patient.
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Figure 5. CTC size varies greatly across patients with mCRPC
A. Cellular area (μm2) per CTC as calculated by Epic software for each patient is plotted. 
White blood cell (WBC) size frequency distribution curve was generated by measuring the 
cellular area of approximately 300 normal WBCs (right side). The blue dashed line 
represents the median WBC area (75 μm2). Red and green dashed lines indicate WBC size 
cut-offs equal to the 25th (64 μm2) and 75th (90 μm2) percentile, respectively. Traditional 
CTCs (blue), CTC clusters (green) and CK− CTCs (purple) are indicated according to the 
legend. Apoptotic CTCs were omitted from analysis due to poor segmentation of fragmented 
nuclei in these cells. B. The percentage of all CTCs for each patient with area greater than 
(non-Small CTC; green) or less than the WBC 75th percentile (Small CTC; red) is plotted. 
*Sample 5037 was not evaluable and is not included in panel A.
McDaniel et al. Page 18
BJU Int. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. Associations of CTC/mL counts and clinicopathological parameters
A. Spearman rank correlation (rs) matrix of CTC/mL counts (All=summed traditional, 
clusters, CK− and apoptotic) and clinicopathological parameters for the 41 patients with 
mCRPC in our cohort. Correlations are given and indicated according to the colour scale in 
the legend). Statistical significance of each comparison is indicated by the cell border 
thickness according to the legend. B. Significant (p<0.05, Mann-Whitney test) associations 
between CTC counts (and clinicopathological parameters) with the presence/absence of 
visceral metastases are shown. C. All, traditional and non-traditional CTC counts stratified 
by patient status (dead vs. alive) at 18 months are plotted (40 of 41 patients evaluable at that 
time point). p values from Mann-Whitney tests are shown. D. Kaplan-Meier analysis for all, 
traditional, and non-traditional CTC counts for overall survival time for all 41 patients. For 
each CTC type, patients were stratified by having > or ≤ median CTC count/mL. Log-rank 
test p values are shown. Plots for each non-traditional CTC type for C&D are shown in 
Figure S2.
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Figure 7. Associations of non-traditional CTC/mL counts in patients with mCRPC and overall 
survival
A. Individual non-traditional CTC type counts (CTC clusters, CK− CTCs and apoptotic 
CTCs) stratified by patient status (dead vs. alive) at 18 months are plotted (40 of 41 patients 
evaluable at that time point). p values from Mann-Whitney tests are shown. D. Kaplan-Meier 
analysis for CTC clusters, CK− CTCs and apoptotic CTCs and overall survival time for all 
41 patients. For each CTC type, patients were stratified by having > or ≤ median CTC 
count/mL. Log-rank test p values are shown.
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Table 1
Demographic and clinical characteristics of patients and healthy volunteers at the time of study inclusion
CRPC patients n=41
Age (yr)
 Median 70
 Range 40–82
Serum PSA (ng/mL)
 Median 90
 Range 2–2532
LDH (U/L)
 Median 170
 Range 112–678
Albumin (g/L)
 Median 35
 Range 24–42
Haemoglobin (g/dL)
 Median 12.2
 Range 8.3–15.5
Sites of metastases
 Bone 39 (95%)
 Nodal 28 (68%)
 Visceral 13 (32%)
ECOG performance score
 0 6 (15%)
 1 33 (80%)
 2 2 (5%)
Previous CRPC therapies (n)
 Median 3
 Range 1–5
Previous therapies
 Bicalutamide 41 (100%)
 Docetaxel 26 (63%)
 Cabazitaxel 4 (10%)
 Abiraterone (AA) 14 (34%)
 Enzalutamide (E) 3 (7%)
 Investigational agents 13 (32%)
Healthy Volunteers n=20
Age (yr)
 Median 33.5
 Range 21–53
Sex
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CRPC patients n=41
 Male 10
 Female 10
CRPC = castration resistant prostate cancer
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